Based on previous genetic proof of concept based on a transgenic mouse strain showing neuron-specific expression of a Thr249Ala/Thr251Ala mutant form of mouse E2F4, Myc tagged at its C-terminus (E2F4DN-myc) [19], we hypothesized that human E2F4DN (hE2F4DN), containing Ala mutations in the Thr248/Thr250 motif, could be used as a therapy for AD. This evidence concerns the gene MYC and Alzheimer disease.